Breakout Ventures closed its third fund with $114 million to invest in early-stage biotechs using AI for drug discovery, lab automation, and computational chemistry.1236
The fund targets founder-led startups from pre-seed to Series A, countering the trend of investors favoring derisked assets; seed/Series A rounds dropped from 228 in 2024 to 191 in 2025.1
Early investments include a University of Chicago spinout developing small-molecule drugs with AI-enhanced analysis and another stealth company on scientific innovation distribution.13
Breakout's previous funds succeeded with exits like Surf Bio acquired by Halozyme for $300M+ and Noetik licensing to GSK for $50M upfront in early 2026.3
Note:
No recent news found in search results on Novo Nordisk safety violations or Eli Lilly's Korea investment as of March 2026.
Sources:
1. https://www.biospace.com/business/ai-focused-fund-breakout-raises-114m-to-support-early-stage-biotechs
2. https://www.thebiointel.com/article/ai-focused-fund-breakout-raises-114m-early-stage-biotech
3. https://www.fiercebiotech.com/biotech/breakout-ventures-launches-114m-ai-focused-fund
6. https://www.businesswire.com/news/home/20260310978565/en/Breakout-Ventures-Launches-Fund-III-with-$114M-to-Continue-Building-the-Future-Powered-by-Science